Background: Natriuretic peptides are diagnostic/prognostic biomarkers in major cardiovascular diseases. We aimed at assessing the predictive role of N-terminal pro-A-type (NT-proANP) and pro-B-type (NT-proBNP) natriuretic peptides levels toward cardiovascular outcome in both stable and unstable coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in a non-primary PCI setting. Methods: A total of 395 patients undergoing PCI with stent implantation for either stable angina (SA) or non ST-elevation acute coronary syndrome (NSTE-ACS) were enrolled. Pre-procedural NT-proANP and NT-proBNP levels were measured. Occurrence of major adverse cardiac events (MACEs), composite of cardiac death, non-fatal myocardial infarction, and clinically driven target lesion revascularization (c-TLR), was the endpoint of the study. Follow up mean time was 48.53 ± 14.69 months. Results: MACEs occurred in forty-four patients (11%) during follow up. Both NT-proANP levels [3170 (2210-4630) vs 2283 (1314-3913) fmol/mL, p = 0.004] and NT-proBNP levels [729 (356-1353) vs 511 (267-1006) fmol/mL, p = 0.04] were significantly higher in patients with MACEs compared to patients without MACEs. Similar results were found when considering hard MACEs (myocardial infarction and cardiac death). NT-proANP levels were significantly higher in patients with c-TLR compared with patients without c-TLR [3705 (2766-5184) vs 2343 (1340-3960) fmol/mL, p = 0.021]. At multivariate analysis, NT-proANP levels were a significant predictor of MACEs (HR 1.09, 95% CI 1.03-1.18, p = 0.04). Kaplan-Meyer curves revealed that patients with elevated NT-proANP levels (>. 2.100 fmol/mL) had a lower MACE free survival (p = 0.003). Conclusions: Both NT-proANP and NT-proBNP levels were higher in CAD patients experiencing MACEs following PCI in a non-primary setting. Notably, only NT-proANP levels significantly affected prognosis after PCI.
Niccoli, G., Conte, F. P. M., Marchitti, S., Montone, R. A., Fracassi, F., Grippo, R., Roberto, M., Burzotta, F., Trani, C., Leone, A. M., Bianchi, F., Di Castro, S., Volpe, M., Crea, F., Rubattu, S., NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation, <<CARDIOVASCULAR REVASCULARIZATION MEDICINE>>, 2016; 17 (3): 162-168. [doi:10.1016/j.carrev.2016.02.012] [http://hdl.handle.net/10807/168091]
NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation
Niccoli, Giampaolo;Conte, Fabrizio Paolo Massimo;Montone, Rocco Antonio;Fracassi, Francesco;Burzotta, Francesco;Trani, Carlo;Leone, Antonio Maria;Crea, Filippo;
2016
Abstract
Background: Natriuretic peptides are diagnostic/prognostic biomarkers in major cardiovascular diseases. We aimed at assessing the predictive role of N-terminal pro-A-type (NT-proANP) and pro-B-type (NT-proBNP) natriuretic peptides levels toward cardiovascular outcome in both stable and unstable coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in a non-primary PCI setting. Methods: A total of 395 patients undergoing PCI with stent implantation for either stable angina (SA) or non ST-elevation acute coronary syndrome (NSTE-ACS) were enrolled. Pre-procedural NT-proANP and NT-proBNP levels were measured. Occurrence of major adverse cardiac events (MACEs), composite of cardiac death, non-fatal myocardial infarction, and clinically driven target lesion revascularization (c-TLR), was the endpoint of the study. Follow up mean time was 48.53 ± 14.69 months. Results: MACEs occurred in forty-four patients (11%) during follow up. Both NT-proANP levels [3170 (2210-4630) vs 2283 (1314-3913) fmol/mL, p = 0.004] and NT-proBNP levels [729 (356-1353) vs 511 (267-1006) fmol/mL, p = 0.04] were significantly higher in patients with MACEs compared to patients without MACEs. Similar results were found when considering hard MACEs (myocardial infarction and cardiac death). NT-proANP levels were significantly higher in patients with c-TLR compared with patients without c-TLR [3705 (2766-5184) vs 2343 (1340-3960) fmol/mL, p = 0.021]. At multivariate analysis, NT-proANP levels were a significant predictor of MACEs (HR 1.09, 95% CI 1.03-1.18, p = 0.04). Kaplan-Meyer curves revealed that patients with elevated NT-proANP levels (>. 2.100 fmol/mL) had a lower MACE free survival (p = 0.003). Conclusions: Both NT-proANP and NT-proBNP levels were higher in CAD patients experiencing MACEs following PCI in a non-primary setting. Notably, only NT-proANP levels significantly affected prognosis after PCI.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
